NIH-funded research Career grant

Investigating how SIN3a affects a key receptor in pulmonary arterial hypertension

Official title: Role of SIN3a in the epigenetic regulation of the Bone Morphogenetic Protein Receptor Type 2 in pulmonary arterial hypertension

Funded at New York Medical College · NIH-10914794 · Data updated 2026-11-12

This study is looking at how a protein called SIN3a affects another protein, BMPR2, which is important for keeping your lung blood vessels healthy, and it hopes to find new ways to help people with pulmonary arterial hypertension (PAH) by understanding how these proteins work together.

More Hypertension research and trials

Quick facts

Grant typeCareer grant
Study typeNIH-funded research
Funding institutionNew York Medical College
NIH-funded
Lab location1 site (Valhalla, United States)
Project startSeptember 1, 2022
Project endAugust 31, 2025
Funding year2024
Award (this year)$135,303
NIH project number5K01HL159038-03
Project IDNIH-10914794 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension or those at risk for developing this condition.

Less likely to help

Patients with pulmonary arterial hypertension caused by factors unrelated to BMPR2 or SIN3a may not benefit from this research.

What this research studies

This research focuses on understanding the role of SIN3a in regulating the Bone Morphogenetic Protein Receptor Type 2 (BMPR2), which is crucial for maintaining healthy blood vessels in the lungs. By exploring the molecular mechanisms that lead to changes in BMPR2 expression, the study aims to uncover how these changes contribute to pulmonary arterial hypertension (PAH), a serious condition characterized by high blood pressure in the lungs. The research involves examining the epigenetic modifications that affect BMPR2 in pulmonary artery endothelial cells, which may provide insights into potential therapeutic targets for PAH. Patients may benefit from a better understanding of the disease mechanisms, potentially leading to new treatment strategies.

Why it matters

Potential benefit: If successful, this research could lead to new therapeutic approaches for treating pulmonary arterial hypertension.

How similar studies have gone: Previous studies have shown promising results in understanding the role of epigenetic factors in vascular diseases, suggesting that this approach could yield valuable insights.

Where this research is happening

  • New York Medical College
    Valhalla, United States
    Active

Researchers

  • Principal investigator: Bisserier, Malik — New York Medical College
  • Study coordinator: Bisserier, Malik

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.